Agents that improve incretin action in the treatment of type 2 diabetes

Marta Wróbel; Aleksandra Szymborska-Kajanek; Anna Psurek; Władysław Grzeszczak; Krzysztof Strojek

ISSN: 1505-8409

Przewodnik Lekarza/Guide for GPs

Current issue Archive About the journal Supplements Contact Instructions for authors

3/2008
vol. 11

Send email

Copy url:

abstract:

Agents that improve incretin action in the treatment of type 2 diabetes

Marta Wróbel

,

Aleksandra Szymborska-Kajanek

,

Anna Psurek

,

Władysław Grzeszczak

,

Krzysztof Strojek

Przew Lek 2008; 3: 24-31

Online publish date: 2008/07/11

View full text Get citation

Preservation of normoglycaemia is a key goal of diabetes treatment. There is a wide gap between the results of glycaemic control in daily practice and the guidelines. Currently incretin hormones are of clinical interest. These are gut hormones which stimulate b-cells to secrete insulin in a glucose-dependent manner. Impairment of the effect of incretin plays a role in the pathogenesis of diabetes. The aim of this article was to present new groups of agents which improve the effect of incretin in treatment of type 2 diabetes.

keywords:

Agents that improve incretin action in the treatment of type 2 diabetes

Marta Wróbel , Aleksandra Szymborska-Kajanek , Anna Psurek , Władysław Grzeszczak , Krzysztof Strojek

incretin hormones, GLP-1 receptor agonist, dipeptidyl peptidase-4 inhibitors, type 2 diabetes

Marta Wróbel

,

Aleksandra Szymborska-Kajanek

,

Anna Psurek

,

Władysław Grzeszczak

,

Krzysztof Strojek